Brazil COVID-19 inquiry told of Bolsonaro's blind faith in chloroquine

By Maria Carolina Marcello BRASILIA (Reuters) - Brazil's former health minister told a parliamentary inquiry on Tuesday that President Jair Bolsonaro's right-wing government knew full well that the treatment they were advocating for COVID-19 patients had no scientific basis. Luiz Henrique Mandetta, who was fired last April by Bolsonaro for not agreeing to push the malaria drug chloroquine as a COVID-19 treatment, testified before a parliamentary inquiry into the handling of the pandemic that has killed more than 408,000 Brazilians.

Reuters May 05, 2021 04:11:58 IST
Brazil COVID-19 inquiry told of Bolsonaro's blind faith in chloroquine

COVID-19 inquiry told of Bolsonaro's blind faith in chloroquine" src="https://images.firstpost.com/wp-content/uploads/reuters/05-2021/05/2021-05-04T204752Z_1_LYNXMPEH43185_RTROPTP_2_BRAZIL-POLITICS.jpg" alt="Brazil COVID19 inquiry told of Bolsonaros blind faith in chloroquine" width="300" height="225" />

By Maria Carolina Marcello

BRASILIA (Reuters) - Brazil's former health minister told a parliamentary inquiry on Tuesday that President Jair Bolsonaro's right-wing government knew full well that the treatment they were advocating for COVID-19 patients had no scientific basis.

Luiz Henrique Mandetta, who was fired last April by Bolsonaro for not agreeing to push the malaria drug chloroquine as a COVID-19 treatment, testified before a parliamentary inquiry into the handling of the pandemic that has killed more than 408,000 Brazilians.

The Senate investigation is expected to hurt the president politically 17 months ahead of elections by showing the country that his opposition to lockdowns and social distancing measures, his failure to secure vaccines and the touting of unproven treatments deepened the crisis Brazil is now in.

"I warned Bolsonaro systematically of the consequences of not adopting the recommendations of science to fight COVID-19 ," Mandetta told the commission.

The minister said he was called to a cabinet meeting with the president, where there was a plan to change the official indications for use of the old anti-malaria drug to say it could be prescribed for COVID-19 .

Antonio Barra Torres, president of Brazil's health regulator Anvisa who was also at the meeting, said that could not be done.

"The government was aware that it was prescribing chloroquine without any scientific evidence," Mandetta said.

Brazil has the highest death toll in the world from COVID-19 after the United States, and third in total coronavirus infections after the United States and India.

The South American country is so short of vaccine supplies that several big cities have not been able to administer second doses. Some intensive care wards have run out of oxygen and drugs needed to sedate intubated COVID-19 patients.

The United States is working to give Brazil access to $20 million worth of medication used for patients in need of mechanical breathing assistance. The medications will come from the U.S. government's strategic stockpile and will be delivered in partnership with the Pan American Health Organization, the White House said on Tuesday.

The Senate investigation has called up other former health ministers, including General Eduardo Pazuello, who was picked by Bolsonaro after two ministers were removed for not backing his chloroquine treatment plan.

Bolsonaro's championing of chloroquine mirrored former U.S. President Donald Trump's lobbying for use of the related drug hydroxychloroquine as a COVID-19 treatment despite a lack of scientific evidence of any benefit for those patients.

Bolsonaro admired Trump and shares many of his ideological views, including playing down the severity of the pandemic.

Pazuello was due to testify on Wednesday, but said he could no appear because he had been in contact with two army colonels who tested positive for COVID-19 . His testimony has been rescheduled for May 19.

(Reporting by Maria Carolina Marcello and Eduadro Simoes; Writing by Anthony Boadle; Editing by Bill Berkrot)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

China's Ximalaya, Qiniu file for U.S. IPOs
News & Analysis

China's Ximalaya, Qiniu file for U.S. IPOs

(Reuters) -Ximalaya, backed by China's Tencent Holdings, filed for an initial public offering (IPO) in the United States on Friday, cashing in on growing demand as more people tune in to podcasts while staying at home during the pandemic. China's Qiniu Ltd, a cloud-based platform-as-a-service provider backed by Alibaba Group Holding Ltd, also filed paperwork for a U.S. IPO

Donerail pushes gaming headset maker Turtle Beach to explore a sale - sources
News & Analysis

Donerail pushes gaming headset maker Turtle Beach to explore a sale - sources

By Greg Roumeliotis (Reuters) - Donerail Group, an investment firm led by former activist hedge fund Starboard Value LP executive Will Wyatt, has amassed a stake in Turtle Beach Corp and is pushing the maker of gaming headsets to explore a sale, people familiar with the matter said on Friday. The move represents a bet that Turtle Beach could attract acquisition interest from peers such as Corsair Gaming Inc and GN Store Nord A/S, as the video game market continues to benefit from people looking for entertainment options at home during the COVID-19 pandemic

Analysis: New meme stocks swing as shorts and retail investors face off again
Business

Analysis: New meme stocks swing as shorts and retail investors face off again

By John McCrank, Saqib Iqbal Ahmed and Lawrence Delevingne NEW YORK (Reuters) - Recent volatility in a handful of so-called meme stocks is putting the spotlight back on the tussle between individual investors and short sellers, months after a wild ride in GameStop captivated Wall Street’s attention. Stocks that have notched big swings this month include laser-manufacturer MicroVision Inc, a favorite on Reddit’s popular WallStreetBets forum, whose shares have risen as much as 170% since April 20 before tumbling in recent days